🕒 Last update: loading…

Stock SELLAS Life Sciences Group, Inc. SLS

SELLAS Life Sciences Group, Inc. — Investlytic score 1/5 on the five criteria.

-
-
20/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 1/5 criteria met.

  • ❌ Price trend failed
  • ❌ Growth failed
  • ✅ Debt passed
  • ❌ P/E failed
  • ❌ Correction failed

Price trend

Overall trend (8 years): insufficient progression (less than x1.5).

Price change 2018 → 2019: -93.01%

Price change 2019 → 2020: 35.12%

Price change 2020 → 2021: -4.82%

Price change 2021 → 2022: -57.32%

Price change 2022 → 2023: -55.08%

Price change 2023 → 2024: -1.89%

Price change 2024 → 2025: 262.50%

Price change 2025 → 2026: 200.53%

Price change 2026 (year to date): 160.46%

Financial growth

Revenue CAGR (8 years): N/A

Earnings CAGR (8 years): N/A

Growth status: insufficient data or negative trend.

Debt

Debt-to-equity ratio: 0.01

Debt/equity < 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio: -55.90

P/E > 25.0 (maximum threshold).

Correction (6 months)

Current correction: 26.71% from the high over 6 months.

Excessive correction (> 20.0%).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, model verdict (buy, watch, sell) and details of the 5 criteria · visible with a free account.

02

Price trend

Price & trend

Interactive chart →
Loading chart…

⚖️ Comparison with the market

All stocks →
StockP/EDette/FPRevenue growthRating
SELLAS Life Sciences Group, Inc.–0.01–🔒
Azenta, Inc.93.20.06+0.0 %–
PolyPeptide Group AG100.80.38+11.8 %–
ANI Pharmaceuticals, Inc.8.20.60+48.0 %★ 4/5
Emeis–6.11+11.4 %–

Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.

03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

+

Key reported figures

Revenue, net income and net margin reported by SELLAS Life Sciences Group, Inc. over the latest fiscal years.

Revenue
1.0 m USD
fiscal year 2022
Net income
-41.3 m USD
fiscal year 2022
Net margin
-4,130.1 %
fiscal year 2022
Average annual growth
-13.3 %
Revenue growth over 5 years
Market cap
1.6 bn USD
Fiscal yearRevenueNet incomeNet marginRevenue growth
20122.0 m-35.0 m-1,715.8 %n/a
20132.5 m-76.7 m-3,083.2 %+22.0 %
20149.3 m-36.6 m-392.8 %+274.7 %
20201.9 m-16.8 m-882.0 %-79.6 %
20217.6 m-20.7 m-272.4 %+300.0 %
20221.0 m-41.3 m-4,130.1 %-86.8 %

Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.

+

Accounts and financial health

Balance sheet and cash flow published by SELLAS Life Sciences Group, Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).

Overview
fragile accounts
according to Altman Z, Piotroski and net debt
Altman Z-score
102.01
safe zone (above 2.99)
Piotroski Score
2 / 9
0 to 3: fragile accounts
Net Debt / EBITDA
3.63 x
high debt
Fiscal year20212022202320242025
Cash and investments21.5 m17.1 m2.5 m13.9 m71.9 m
Total Debt808,000945,000906,0001.0 m1.0 m
Net Debt-20.6 m-16.2 m-1.6 m-12.9 m-70.9 m
Equity20.3 m4.9 m-8.0 m9.5 m70.9 m
Total assets26.4 m20.9 m6.2 m19.4 m78.3 m
Operating cash flow-26.0 m-23.8 m-31.4 m-35.4 m-28.4 m
Investments (capex)04.5 m5.5 m00
Free cash-flow-26.0 m-28.3 m-36.9 m-35.4 m-28.4 m
Share buybacks00000
Dividends paid00000

Amounts in USD, currency of the published accounts.

Trailing 12-month ratios

Price / earnings (P/E)-40.41 x
Price / book value12.33 x
Return on Equity (ROE)-31.9 %
Return on Invested Capital (ROIC)-29.8 %
Net margin0.0 %
Debt / equity0.00 x
Current ratio14.92 x
Free cash-flow yield-1.7 %

Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 18/11/2026.

+

Valuation and competitors

SELLAS Life Sciences Group, Inc. compared with its sector on the same exchange and with its main competitors.

Sector median P/E
20.8
healthcare, Nasdaq
Sector over 10 years
28.2
10-year median, range 20.4 to 45.8

Direct competitors

CompanyMarket cap (USD)P/ENet margin
SELLAS Life Sciences Group, Inc.1.6 bnn/a0.0 %
ArriVent BioPharma, Inc. Common Stock AVBP673 mn/a0.0 %
Incyte Corporation INCY24.7 bn16.325.0 %
MacroGenics, Inc. MGNX141 mn/a-49.9 %
Nurix Therapeutics, Inc. NRIX1.7 bn6.7-314.9 %
Immunome, Inc. IMNM2.2 bnn/a-3,060.0 %
ASCENTAGE PHARMA GROUP INTERNATIONAL AAPG1.4 bnn/a-216.5 %
Prelude Therapeutics Incorporated PRLD200 mn/a-819.6 %
IDEAYA Biosciences, Inc. IDYA3.1 bnn/a-52.0 %
Sector median (Nasdaq)20.8

Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 13/11/2026. Competitors: comparable companies named by the data provider.

+

Analyst consensus and forecasts

What the financial analysts covering SELLAS Life Sciences Group, Inc. publish: ratings, price targets and earnings forecasts.

Majority rating
buy
5 analysts

Breakdown of ratings

strong buy 0buy 5hold 0sell 0strong sell 0

Price targets: published for companies listed in the United States only.

Track record against expectations: reported EPS above consensus 8 times over the last 12 releases.

Source: ratings and forecasts published by analysts, collected on 14/11/2026. An analyst rating or target is not a guarantee.

+

Dividends and earnings

SELLAS Life Sciences Group, Inc.: dividend history, last distributions, stock splits and earnings releases.

No known dividend for this company.

Earnings releases

DatePublished EPSExpected EPSSurprise
12/11/2026-0.05-0.05n/a
11/08/2026-0.05-0.04n/a
12/05/2026-0.05-0.06n/a
19/03/2026-0.05-0.06n/a
12/11/2025-0.06-0.06n/a
12/08/2025-0.07-0.08n/a

Stock splits

DateOperation
08/11/2019reverse split: 1 share for 50
02/01/2018reverse split: 1 share for 30
14/11/2016reverse split: 1 share for 20

Factual data: ex-dividend history and earnings calendar, as of 18/11/2026. A past dividend does not guarantee the next one.

+

Who owns the stock

Free float, institutional investors, large funds, executives and elected officials: declared positions in SELLAS Life Sciences Group, Inc.

Free float
99.8 %
share of freely traded shares
Large funds tracked
16
hold the stock as of 2026Q2

Large funds tracked

FundSharesValue (USD)Weight in the fundChangeQuarter
State Street26.0 m384 m0.0 %+209.6 %2026Q2
BlackRock15.1 m222 m0.0 %+23.5 %2026Q2
Geode Capital Management4.9 m72.1 m0.0 %+24.8 %2026Q2
Vanguard Group8.5 m31.9 m0.0 %+23.8 %2025Q4
Northern Trust1.6 m23.9 m0.0 %+27.0 %2026Q2
Morgan Stanley1.2 m18.2 m0.0 %-7.5 %2026Q2
Bank of America787,94911.6 m0.0 %+22.8 %2026Q2
Wellington Management597,3098.8 m0.0 %+73.2 %2026Q2

Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 18/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.

+

PEA and practical information

PEA eligibility
no
head office outside the EU and EEA
Listing exchange
Nasdaq
IPO: 12/03/2008
ISIN code
US81642T2096
Workforce
15
full-time employees
Chief executive
Angelos M. Stergiou ScD h.c.

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about SELLAS Life Sciences Group, Inc.

What is the SELLAS Life Sciences Group, Inc. share price?

Latest recorded price: 7.86 USD on 13/11/2026, for a market cap of 1.6 bn USD.

What is the revenue of SELLAS Life Sciences Group, Inc.?

1.0 m USD for fiscal year 2022, with net income of -41.3 m USD (net margin -4,130.1 %).

What do analysts say about SELLAS Life Sciences Group, Inc.?

Out of 5 analysts: 5 buy or strong buy, 0 hold, 0 sell or strong sell.

Is SELLAS Life Sciences Group, Inc. stock eligible for the French PEA?

No: the company is headquartered outside the European Union and the European Economic Area (ISIN US81642T2096).

How many employees does SELLAS Life Sciences Group, Inc. have?

15 full-time employees according to the latest published profile.

Who runs SELLAS Life Sciences Group, Inc.?

Angelos M. Stergiou ScD h.c. is the company's chief executive.

Which large funds own SELLAS Life Sciences Group, Inc.?

As of 2026Q2, among the large funds tracked: State Street, BlackRock, Geode Capital Management, Vanguard Group, Northern Trust.

07

Similar stocks